Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331533 | 1.00 | MEN1 (0.40) | MEN1KMT2ARAB9ANPC1KDM4E | |
| SCHEMBL3332084 | 0.76 | CCR1 (0.47) | MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL3332842 | 0.75 | MEN1 (0.37) | MEN1KMT2ARAB9ANPC1KDM4E | |
| SCHEMBL3332836 | 0.75 | MEN1 (0.37) | MEN1KMT2ARAB9ANPC1KDM4E | |
| SCHEMBL14551225 | 0.74 | MEN1 (0.48) | MEN1KMT2ARAB9ANPC1ATM | |
| SCHEMBL737630 | 0.71 | CCR1 (0.41) | KMT2ARAB9AKDM4ELMNAMAPT | |
| SCHEMBL3336371 | 0.68 | MEN1 (0.36) | MEN1KMT2ARAB9ANPC1KDM4E | |
| SCHEMBL3336374 | 0.68 | MEN1 (0.36) | MEN1KMT2ARAB9ANPC1KDM4E | |
| SCHEMBL29344102 | 0.67 | ENPP3 (0.36) | KDM4E | |
| SCHEMBL29937015 | 0.67 | ENPP3 (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2139888-A2 | IMIDAZOÝ1,2-A¨PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008121687-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | MEN1 3157/4885KMT2A 1354/4885RAB9A 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.